Leadership + Team
Our management team has extensive pharma and industry experience and a track record of drug development successes.
Leadership
Klaus Dugi, MD
Chief Executive Officer
Klaus Dugi, MD
Chief Executive Officer
Klaus Dugi, MD, brings over 18 years of leadership in global pharmaceutical companies, including nine years as Chief Medical Officer at Boehringer Ingelheim and Ferring Pharmaceuticals. During his tenure, he oversaw the development and launch of four blockbuster drugs and holds 17 patents. His experience spans clinical development, medical affairs, and commercial leadership as General Manager for the UK & Ireland at Boehringer.
Klaus also serves on the boards of AOBiome and Ferring Ventures and is an Adjunct Professor of Medicine at Heidelberg University. Earlier in his career, he conducted research at the U.S. National Institutes of Health and has published extensively in peer-reviewed journals.
Pénélope Andreux, PharmD, PhD
Chief Scientific Officer
Pénélope Andreux, PharmD, PhD
Chief Scientific Officer
Pénélope has 15+ years of expertise in mitochondrial research with a focus on the early discovery and development of small molecules to improve mitochondrial function, with over 20 publications in leading journals such as Cell and Nature Medicine and contributing to more than 10 patents.
Penelope Andreux earned a Doctor of Pharmacy (Pharm.D.) degree from the University of Strasbourg in France and later completed a Ph.D. in Genetics and Pharmacology of Metabolism at EPFL, Lausanne, Switzerland, in the laboratory of Pr. Johan Auwerx.
Peter Harboe-Schmidt, MSc, MBA
Head of Finance
Peter Harboe-Schmidt, MSc, MBA
Head BD & Finance
Peter brings over 30 years of leadership and entrepreneurial experience in the life sciences industry, specializing in business development, finance, and marketing. He has held senior roles, including Head of Business Planning at Amgen Europe and Head of Marketing & Sales at DuPont Denmark.
As an entrepreneur, Peter has founded and co-founded five life science companies and was part of the management team that led Modex Therapeutics through its successful IPO.
Leila Mirmohamadsadeghi, PhD
Director Preclinical Operations
Leila Mirmohamadsadeghi, PhD
Director Preclinical Operations
Leila brings with her a robust background and mindset of a problem-solver thanks to her engineering degrees from EPFL.
Within her nine years of experience in the pharmaceutical industry, Leila has led operations in a variety of areas such as CMC, toxicology, ADME, medical affairs, medical education, medical events, medical information, investigator-initiated studies, early access programs, quality and compliance; supporting products on the market or in development for disease areas including oncology, GI and CNS among others.
Anke Post, MD, PhD
Chief Medical Officer
Anke Post, MD, PhD
Chief Medical Officer
Dr. Post has held senior medical and translational leadership positions in major pharmaceutical companies, including Novartis, Eli Lilly, and Roche, where she was responsible for global neuroscience programs. In addition, she has demonstrated strong executive leadership in biotech and medtech, serving as Chief Medical Officer or senior executive in multiple innovative companies, such as AC Immune, GeNeuro, FeetMe, and uniQure, successfully bridging early scientific innovation to clinical application.
Dr. Anke Post is a physician-scientist with deep expertise in neuroscience, and a strong academic and clinical background. She obtained her a specialisation degree in Psychiatry & Psychotherapy from the Charité in Berlin and the Max Planck Institute of Psychiatry, and completed her habilitation at the Ludwig Maximilian University in Munich. She brings over 20 years of experience in R&D and medical leadership, combining senior clinical roles with extensive expertise in translational and clinical development across neurological and psychiatric indications.
Guillermo Elias, PhD
Head of Business Development
Guillermo Elias, PhD
Head of business Development
Guillermo Elias, Ph.D., brings over 17 years of experience in business development, corporate strategy, corporate financing, commercialization and operational leadership in healthcare companies across the USA and Switzerland. He has held leadership roles with increasing responsibilities in multinationals, mid-stage and early-stage companies including Roche Pharmaceuticals, Genentech, Corvus Pharmaceuticals, iPierian (acquired by Bristol Myers Squibb), Molecular Stethoscope (now Superfluid Dx) and Proximity Therapeutics.
Most recently, Guillermo led two biotechnology companies in Silicon Valley and Boston, serving as Chief Executive Officer, President, and Board Member. His expertise spans neurology, oncology, cardio-metabolic, and immunological diseases. Guillermo earned a Ph.D. in neuroscience at the University of California, San Francisco, and studied business entrepreneurship and administration at Stanford University and IE University Business School.
Team
Our team has the skills to translate innovative science into first-in-class therapeutics.
Alexandre Guillon, MSc
Research Assistant
Reetta Holmila, PhD
Senior Scientist
Silke Kern
Clinical Operations Manager
Jana Majesrka
Senior Scientist
Marko Milosavljevic
Office manager
Michele Vigolo, PhD
Senior Scientist
